GSK antibody falls short in hospitalized Covid-19 patients, but may help elderly February 25, 2021 Auto Bot BioPharma, biopharma nl, Clinical Trials, GlaxoSmithKline, Pharma, United Kingdom 0 Though GlaxoSmithKline’s drug otilimab missed the main goal of a mid-stage Covid-19 study, the company points to better data in a subgroup of older patients. GSK is expanding the study in patients 70 and older in hopes of replicating those results.